We next evaluated the activity and toxicity of the regimen combining TPL and ABT-199 in two xenograft models bearing either MOLM-13 or MV4–11 cells, both of which carry FLT-ITD, representing an AML subset with poor clinical outcomes. The gene discussed is FLT1; the disease is acute myeloid leukemia.